According to Huang’s report, for patients with ESCC with high EGFR expression, cetuximab could not only improve survival but also reduce the recurrence and metastatic potential of the tumor.14 Combining cetuximab with chemotherapy drugs is a novel strategy for esophageal cancer therapy. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.